Phenotypes Associated with This Genotype

Genotype
MGI:5473527

• Allelic Composition: Pomc^tm2Low/Pomc^tm2Low; Tg(CAG-cre/Esr1*)5Amc/0
• Genetic Background: involves: 129S4/SvJae * C57BL/6 * CBA

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

Obesity in Pomc^tm2Low/Pomc^tm2Low Tg(CAG-cre/Esr1*)5Amc/0 females and weight loss following tamoxifen treatment

growth/size/body

increased lean body mass ( J:194013 )

• in vehicle treated mice

increased body length ( J:194013 )

• in vehicle treated mice

abnormal body weight ( J:194013 )

• mice treated with tamoxifen at P60 or P180 exhibit rapid weight loss for 3 weeks followed by a plateau and resumption of weight gain

increased body weight ( J:194013 )

• in vehicle-treated mice

• in male mice treated with tamoxifen at P60 or P180

• however, mice exhibit normal weight when with tamoxifen at P25 exhibit normal weight or when male mice are subjected to caloric restriction and returned to ad libitum feeding with tamoxifen treatment at P60

increased susceptibility to weight gain ( J:194013 )

• in vehicle-treated mice

• in male mice treated with tamoxifen at P60 or P180

• however, mice exhibit normal weight when with tamoxifen at P25 exhibit normal weight or when male mice are subjected to caloric restriction and returned to ad libitum feeding with tamoxifen treatment at P60

increased liver weight ( J:194013 )

• in vehicle treated mice

• however, tamoxifen treatment restores liver weight

homeostasis/metabolism

increased circulating glucose level ( J:194013 )

• in vehicle treated mice and to a lesser extent in mice treated with tamoxifen at P180

increased circulating insulin level ( J:194013 )

• in vehicle treated mice and to a lesser extent in mice treated with tamoxifen at P180

increased circulating leptin level ( J:194013 )

• in vehicle treated mice and to a lesser extent in mice treated with tamoxifen at P180

decreased oxygen consumption ( J:194013 )

• regardless of tamoxifen treatment

insulin resistance ( J:194013 )

• in vehicle treated mice and to a lesser extent in mice treated with tamoxifen at P180

adipose tissue

increased total body fat amount ( J:194013 )

• in vehicle treated mice

• however, tamoxifen treatment restores body fat

increased gonadal fat pad weight ( J:194013 )

♂ • in vehicle treated male mice

♂ • however, tamoxifen treatment at P25, P60 or P180 restores fat pad weight

increased inguinal fat pad weight ( J:194013 )

• in vehicle treated mice

• however, tamoxifen treatment at P25, P60 or P180 restores fat pad weight

increased retroperitoneal fat pad weight ( J:194013 )

• in vehicle treated mice

• however, tamoxifen treatment at P60 or P180 restores fat pad weight

behavior/neurological

decreased food intake ( J:194013 )

• in the first 2 to 3 weeks following tamoxifen-treatment

decreased compensatory feeding amount ( J:194013 )

• following a 24 hour fast in vehicle treated mice

• however, tamoxifen restores fast-induced hyperphagia

polyphagia ( J:194013 )

• in vehicle treated mice

• however, tamoxifen treatment at P25, P60 or P180 restores daily food intake

decreased locomotor activity ( J:194013 )

• in vehicle treated mice

• however, tamoxifen treatment restores activity

liver/biliary system

increased liver weight ( J:194013 )

• in vehicle treated mice

• however, tamoxifen treatment restores liver weight

hepatic steatosis ( J:194013 )

• in vehicle treated mice

• however, tamoxifen treatment restores liver fat content